Advertisement

Cytokinetics Inc (CYTK) Q2 2020 Earnings Call Transcript

Cytokinetics Inc (CYTK) Q2 2020 Earnings Call Transcript

Robert Blum, our President and Chief Executive Officer, will kick off the call with an overview of the quarter and our recent progress. Then Fady Malik, our EVP of Research and Development, will provide updates on key developments for omecamtiv mecarbil, our cardiac myosin activator being developed under our collaboration with Amgen, and the expanded and accelerated development plan for CK-274, our next in class cardiac myosin inhibitor.